Immunome (NASDAQ:IMNM) Now Covered by Analysts at Guggenheim

Guggenheim assumed coverage on shares of Immunome (NASDAQ:IMNM) in a report issued on Monday, Marketbeat Ratings reports. The firm issued a buy rating and a $35.00 price objective on the stock.

Several other equities analysts also recently commented on IMNM. Leerink Partnrs reiterated an outperform rating on shares of Immunome in a report on Monday, January 29th. Wedbush upped their price target on shares of Immunome from $27.00 to $33.00 and gave the company an outperform rating in a research note on Monday, April 1st. Finally, SVB Leerink started coverage on shares of Immunome in a report on Monday, January 29th. They issued an outperform rating and a $30.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of Buy and a consensus price target of $32.67.

Immunome Trading Down 5.5 %

IMNM stock opened at $17.38 on Monday. Immunome has a 1-year low of $4.44 and a 1-year high of $30.96. The business’s 50 day simple moving average is $23.16 and its 200 day simple moving average is $14.80. The firm has a market capitalization of $1.04 billion, a PE ratio of -3.22 and a beta of 1.66.

Hedge Funds Weigh In On Immunome

A number of hedge funds have recently bought and sold shares of IMNM. Vanguard Group Inc. boosted its holdings in Immunome by 339.0% in the 4th quarter. Vanguard Group Inc. now owns 1,740,026 shares of the company’s stock valued at $18,618,000 after purchasing an additional 1,343,697 shares during the period. Avidity Partners Management LP bought a new stake in shares of Immunome in the fourth quarter valued at approximately $14,268,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Immunome by 505.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,051,222 shares of the company’s stock valued at $11,249,000 after buying an additional 877,592 shares during the period. Point72 Asset Management L.P. acquired a new stake in Immunome during the second quarter worth approximately $3,307,000. Finally, TD Asset Management Inc bought a new position in Immunome during the 3rd quarter worth $1,063,000. 44.58% of the stock is owned by institutional investors.

About Immunome

Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.